Coya Therapeutics Inc (COYA)

$4.29 +0.11 (2.63%)
Market Cap 98.05M
Revenue (ttm) 7.95M
Net Income (ttm) -21.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -267.04%
Debt to Equity Ratio 0.00
Volume 512,500
Avg Vol 149,492
Day's Range N/A - N/A
Shares Out 23.46M
Stochastic %K 84%
Beta 0.55
Analysts Strong Sell
Price Target $15.64

Company Profile

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated...

Industry: Biotechnology
Sector: Healthcare
Phone: 800 587 8170
Address:
5850 San Felipe St., Suite 500, Houston, United States
zampy
zampy May. 13 at 11:01 AM
$COYA Continued...The unique delivery method can be expanded in other areas like FTD and Alzheimers. The impact of fast track. The fast track granted yesterday acts as a valuation floor. It tells a potential suitor the path is greased. If BMY were to buy COYA now they have a rolling review allowing them to submit their own massive regulatory resources to the FDA immediately, rather then waiting for COYA ti finish up on a start up budget. BNY needs to replace revenues from patent expirations. COYA validated its science on April 9th undeniable #s. And COYA just got the fast track. In the biotech world this is where the bigs...Sanofi..LLY..BMY.. start making phone calls. The goal is for BMY ti buy before topline as when top line hits could pay 5x ad high. People think it only will be Dr Reddy's because they're on the hook for 700m in milestones and now own 9.7%. I actually believe Dr Reddy's will need to do a deal in the next 4 months or else lose this to BMY.
0 · Reply
zampy
zampy May. 13 at 10:46 AM
$COYA Speculation on BMY: Yeaterday BMY formed an strategic alliance with Hengrui Pharma for 15.2 billion dollars. These are in 13 assets most in pre clinical or early clinical stages. This proves Bristol Myers is in a buying mood for clinical assets prior to finish lime in Immunology and oncology. Why this fits COYA. BMY has a keen interest in Immunotherapy and T Cell regulation. COYA'S focus in TREGS aligns perfectly with BMY immunology portfolio. Not to mention Dr Arun Swaminathan worked at BMY for 15 years on CTLA4 abatacept. The April 9th data factor is crucial it showed a correlation between longitudinal biomarkers and clinical outcomes. Coya proved their hitting the right biological markers in the blood. Fir BMY a sophisticated buyer this is often enough proof to buy before the final ALSFRS-R scores. The double play. COYA 302 is a combination therapy. Large pharma loves platform plays where they can acquire a unique delivery method.
0 · Reply
Jwa68
Jwa68 May. 12 at 9:04 PM
$COYA value buyers who understand strong fundamentals and have the attention span beyond a day, are likely to do very well in upcoming months. Legacy supply should be almost exausted, paving way to a return to a more equitable valuation.
0 · Reply
irf944
irf944 May. 12 at 8:36 PM
$COYA P&F chart upate. This is a shorter (more sensitive) P&F chart that I thouhgt worthwhile posting after today's price action...which was very encouraging since Demand (X) took over from Supply (O). Below is what has been transpiring which is evident on the chart. We formed a consolidated base from $4.07 to $4.325 over the most recent period. We actually covered the entire range today and added an "X" (denoted demand in charge of the stock) today at $4.325 which is a double top. Next stop I am looking at is $4.55 which will be a break of the current double top (very Bullish) . After $4.55 we are lookign to break the resistance line at $4.73. That's an important break and it's only $0.43 cents away. Will supply drying up we can cover that groudn quickly. We then head back into the $5S
1 · Reply
zampy
zampy May. 12 at 8:32 PM
$COYA I believe with today's news COYA can get a bla submission late 2026...huge catalyst like CLNN did on May 6th.... We are in the fast lane now like CLNN.... #1 We now get more face time with the FDA over the bla. #2 Rolling submission. Not 1 bang..we can send the non clinical and manufacturing parts early. #3 Priority review eligibility. FDA'S final review goes from 10 months to 6 months now!!! We are in the same lane as CLNN maybe 2 to 3 months behind.
1 · Reply
zampy
zampy May. 12 at 8:22 PM
$COYA We crossed the 20 day and 50 day ...$4.24 and $4.25.....I defer to our resident chart guy IRF.....
2 · Reply
Flight510
Flight510 May. 12 at 7:18 PM
$COYA CEO already flush with cash. Adds ATM, while FDA puts him on fast track. Many things happening concurrently. Are we advancing to the final negotiating table? I am pondering. All comments welcome. 
1 · Reply
zampy
zampy May. 12 at 6:12 PM
$COYA VWAP IS $4.13 for the day
0 · Reply
SpaceCityKid
SpaceCityKid May. 12 at 5:46 PM
$COYA Beat on both earnings and revenue, not to mention FDA fast track. Big boys are taking notice. Looks like a probable "hammer" reversal.
0 · Reply
Jwa68
Jwa68 May. 12 at 5:29 PM
$COYA D.Boral, BTIG and Lakestreet all reiterated. $15 target,$16 target and $17 target respectively.
0 · Reply
Latest News on COYA
Coya Therapeutics granted FDA Fast Track Designation for COYA 302

2026-05-12T11:54:30.000Z - 1 day ago

Coya Therapeutics granted FDA Fast Track Designation for COYA 302

Coya Therapeutics reports Q1 EPS (32c), consensus (39c)

2026-05-12T11:49:47.000Z - 1 day ago

Coya Therapeutics reports Q1 EPS (32c), consensus (39c)

Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

May 12, 2026, 7:35 AM EDT - 1 day ago

Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

May 12, 2026, 7:30 AM EDT - 1 day ago

Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics announces publication of research on COYA 302

2026-04-09T12:26:37.000Z - 4 weeks ago

Coya Therapeutics announces publication of research on COYA 302

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

Apr 9, 2026, 8:00 AM EDT - 4 weeks ago

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

Coya Therapeutics Executive Chairman Howard Berman steps down

2026-04-02T12:17:50.000Z - 5 weeks ago

Coya Therapeutics Executive Chairman Howard Berman steps down

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

Apr 2, 2026, 8:00 AM EDT - 5 weeks ago

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

Coya publishes study showing reduction in regulatory T cell function in FTD

2026-03-18T12:38:33.000Z - 2 months ago

Coya publishes study showing reduction in regulatory T cell function in FTD

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Mar 18, 2026, 8:00 AM EDT - 2 months ago

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

Mar 16, 2026, 8:00 AM EDT - 2 months ago

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

Coya Therapeutics Transcript: Status update

Feb 17, 2026, 3:00 PM EST - 3 months ago

Coya Therapeutics Transcript: Status update

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Feb 10, 2026, 8:00 AM EST - 3 months ago

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Coya Therapeutics to sell 2.522M shares at $4.40 in private placement

2026-01-30T13:15:29.000Z - 3 months ago

Coya Therapeutics to sell 2.522M shares at $4.40 in private placement

RDY

Coya Therapeutics Announces $11.1 Million Private Placement

Jan 30, 2026, 8:00 AM EST - 3 months ago

Coya Therapeutics Announces $11.1 Million Private Placement

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Jan 20, 2026, 8:00 AM EST - 4 months ago

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

Jan 8, 2026, 8:00 AM EST - 4 months ago

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

Coya Therapeutics announces FDA acceptance of COYA 302 IND application

2026-01-05T13:05:21.000Z - 4 months ago

Coya Therapeutics announces FDA acceptance of COYA 302 IND application

Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)

Jan 5, 2026, 8:00 AM EST - 4 months ago

Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)

Coya announces Health Canada acceptance of COYA 302 clinical trial application

2025-12-23T13:11:52.000Z - 5 months ago

Coya announces Health Canada acceptance of COYA 302 clinical trial application

Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Dec 23, 2025, 8:00 AM EST - 5 months ago

Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics commences dosing in ALSTARS trial

2025-12-09T13:11:58.000Z - 5 months ago

Coya Therapeutics commences dosing in ALSTARS trial

Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS

Dec 9, 2025, 8:00 AM EST - 5 months ago

Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS

Coya Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 8:45 AM EST - 5 months ago

Coya Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences

Nov 25, 2025, 8:00 AM EST - 6 months ago

Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences

Coya Therapeutics reports Q3 EPS (13c), consensus (30c)

2025-11-12T13:20:43.000Z - 6 months ago

Coya Therapeutics reports Q3 EPS (13c), consensus (30c)

Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Nov 12, 2025, 8:00 AM EST - 6 months ago

Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics price target raised to $17 from $16 at Lake Street

2025-11-05T13:50:45.000Z - 6 months ago

Coya Therapeutics price target raised to $17 from $16 at Lake Street

Coya Therapeutics announces results from COYA 303 in vivo animal study

2025-11-04T14:06:05.000Z - 6 months ago

Coya Therapeutics announces results from COYA 303 in vivo animal study

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

Nov 4, 2025, 8:00 AM EST - 6 months ago

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Oct 27, 2025, 4:01 PM EDT - 7 months ago

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Coya Therapeutics 3.64M Spot Secondary priced at $5.50

2025-10-24T10:35:20.000Z - 7 months ago

Coya Therapeutics 3.64M Spot Secondary priced at $5.50

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

Oct 24, 2025, 6:30 AM EDT - 7 months ago

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

Coya Therapeutics announces common stock offering, no amount given

2025-10-23T20:35:37.000Z - 7 months ago

Coya Therapeutics announces common stock offering, no amount given

Coya Therapeutics Announces Proposed Public Offering of Common Stock

Oct 23, 2025, 4:31 PM EDT - 7 months ago

Coya Therapeutics Announces Proposed Public Offering of Common Stock

Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function

Oct 7, 2025, 8:00 AM EDT - 7 months ago

Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function

Coya Therapeutics completes enrollment in IL-2 and CTLA4-Ig study

2025-09-29T12:10:10.000Z - 8 months ago

Coya Therapeutics completes enrollment in IL-2 and CTLA4-Ig study

Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia

Sep 29, 2025, 8:00 AM EDT - 8 months ago

Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia

Coya Therapeutics launches ALSTARS Trial to study efficacy of COYA 302

2025-09-22T12:15:58.000Z - 8 months ago

Coya Therapeutics launches ALSTARS Trial to study efficacy of COYA 302

Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis

Sep 22, 2025, 8:00 AM EDT - 8 months ago

Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis

Coya Therapeutics’ COYA 303 shows anti-inflammatory effect in animal study

2025-09-16T12:05:25.000Z - 8 months ago

Coya Therapeutics’ COYA 303 shows anti-inflammatory effect in animal study

Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model

Sep 16, 2025, 8:00 AM EDT - 8 months ago

Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model

Coya Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025, 10:00 AM EDT - 8 months ago

Coya Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Coya Therapeutics’ COYA 302 ALS trial accepted by NEALS research consortium

2025-09-04T12:10:30.000Z - 8 months ago

Coya Therapeutics’ COYA 302 ALS trial accepted by NEALS research consortium

Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial

Sep 4, 2025, 8:00 AM EDT - 8 months ago

Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial

PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies

Sep 3, 2025, 11:50 AM EDT - 8 months ago

PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies

Coya Therapeutics to Participate at Upcoming September Investor Conferences

Sep 3, 2025, 8:34 AM EDT - 9 months ago

Coya Therapeutics to Participate at Upcoming September Investor Conferences

Coya receives $4.2M milestone payment after FDA approval of IND for Coya 302

2025-08-25T12:05:29.000Z - 9 months ago

Coya receives $4.2M milestone payment after FDA approval of IND for Coya 302

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Aug 25, 2025, 8:00 AM EDT - 9 months ago

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update

Aug 12, 2025, 8:00 AM EDT - 9 months ago

Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease

Jul 24, 2025, 8:15 AM EDT - 10 months ago

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease

Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025

Jul 22, 2025, 8:15 AM EDT - 10 months ago

Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025

Coya Therapeutics Transcript: IAccess Alpha Virtual Best Ideas Summer Investment Conference 2025

Jun 24, 2025, 10:30 AM EDT - 11 months ago

Coya Therapeutics Transcript: IAccess Alpha Virtual Best Ideas Summer Investment Conference 2025

Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025

Jun 18, 2025, 8:15 AM EDT - 11 months ago

Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025

Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations

Coya Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 12:30 PM EDT - 1 year ago

Coya Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 16, 2025, 10:53 AM EDT - 1 year ago

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

May 13, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

May 8, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

May 8, 2025, 5:00 AM EDT - 1 year ago

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

REPL

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Apr 24, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Coya Therapeutics Transcript: Planet MicroCap Showcase: VEGAS 2025

Apr 23, 2025, 2:00 PM EDT - 1 year ago

Coya Therapeutics Transcript: Planet MicroCap Showcase: VEGAS 2025

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

Apr 21, 2025, 9:51 AM EDT - 1 year ago

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

Apr 1, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Mar 26, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

Mar 18, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations

Feb 25, 2025, 8:15 AM EST - 1 year ago

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations

Coya Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 10:00 AM EST - 1 year ago

Coya Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Feb 6, 2025, 8:00 AM EST - 1 year ago

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:15 AM EST - 1 year ago

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Jan 21, 2025, 8:15 AM EST - 1 year ago

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

Dec 18, 2024, 8:15 AM EST - 1 year ago

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

Coya Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 3, 2024, 12:55 PM EST - 1 year ago

Coya Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

Nov 25, 2024, 8:15 AM EST - 1 year ago

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results

Nov 6, 2024, 8:00 AM EST - 1 year ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results

Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer

Nov 1, 2024, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer

Coya Therapeutics Transcript: Study Update

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Coya Therapeutics Transcript: Study Update

Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial

Oct 29, 2024, 6:41 AM EDT - 1 year ago

Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial

zampy
zampy May. 13 at 11:01 AM
$COYA Continued...The unique delivery method can be expanded in other areas like FTD and Alzheimers. The impact of fast track. The fast track granted yesterday acts as a valuation floor. It tells a potential suitor the path is greased. If BMY were to buy COYA now they have a rolling review allowing them to submit their own massive regulatory resources to the FDA immediately, rather then waiting for COYA ti finish up on a start up budget. BNY needs to replace revenues from patent expirations. COYA validated its science on April 9th undeniable #s. And COYA just got the fast track. In the biotech world this is where the bigs...Sanofi..LLY..BMY.. start making phone calls. The goal is for BMY ti buy before topline as when top line hits could pay 5x ad high. People think it only will be Dr Reddy's because they're on the hook for 700m in milestones and now own 9.7%. I actually believe Dr Reddy's will need to do a deal in the next 4 months or else lose this to BMY.
0 · Reply
zampy
zampy May. 13 at 10:46 AM
$COYA Speculation on BMY: Yeaterday BMY formed an strategic alliance with Hengrui Pharma for 15.2 billion dollars. These are in 13 assets most in pre clinical or early clinical stages. This proves Bristol Myers is in a buying mood for clinical assets prior to finish lime in Immunology and oncology. Why this fits COYA. BMY has a keen interest in Immunotherapy and T Cell regulation. COYA'S focus in TREGS aligns perfectly with BMY immunology portfolio. Not to mention Dr Arun Swaminathan worked at BMY for 15 years on CTLA4 abatacept. The April 9th data factor is crucial it showed a correlation between longitudinal biomarkers and clinical outcomes. Coya proved their hitting the right biological markers in the blood. Fir BMY a sophisticated buyer this is often enough proof to buy before the final ALSFRS-R scores. The double play. COYA 302 is a combination therapy. Large pharma loves platform plays where they can acquire a unique delivery method.
0 · Reply
Jwa68
Jwa68 May. 12 at 9:04 PM
$COYA value buyers who understand strong fundamentals and have the attention span beyond a day, are likely to do very well in upcoming months. Legacy supply should be almost exausted, paving way to a return to a more equitable valuation.
0 · Reply
irf944
irf944 May. 12 at 8:36 PM
$COYA P&F chart upate. This is a shorter (more sensitive) P&F chart that I thouhgt worthwhile posting after today's price action...which was very encouraging since Demand (X) took over from Supply (O). Below is what has been transpiring which is evident on the chart. We formed a consolidated base from $4.07 to $4.325 over the most recent period. We actually covered the entire range today and added an "X" (denoted demand in charge of the stock) today at $4.325 which is a double top. Next stop I am looking at is $4.55 which will be a break of the current double top (very Bullish) . After $4.55 we are lookign to break the resistance line at $4.73. That's an important break and it's only $0.43 cents away. Will supply drying up we can cover that groudn quickly. We then head back into the $5S
1 · Reply
zampy
zampy May. 12 at 8:32 PM
$COYA I believe with today's news COYA can get a bla submission late 2026...huge catalyst like CLNN did on May 6th.... We are in the fast lane now like CLNN.... #1 We now get more face time with the FDA over the bla. #2 Rolling submission. Not 1 bang..we can send the non clinical and manufacturing parts early. #3 Priority review eligibility. FDA'S final review goes from 10 months to 6 months now!!! We are in the same lane as CLNN maybe 2 to 3 months behind.
1 · Reply
zampy
zampy May. 12 at 8:22 PM
$COYA We crossed the 20 day and 50 day ...$4.24 and $4.25.....I defer to our resident chart guy IRF.....
2 · Reply
Flight510
Flight510 May. 12 at 7:18 PM
$COYA CEO already flush with cash. Adds ATM, while FDA puts him on fast track. Many things happening concurrently. Are we advancing to the final negotiating table? I am pondering. All comments welcome. 
1 · Reply
zampy
zampy May. 12 at 6:12 PM
$COYA VWAP IS $4.13 for the day
0 · Reply
SpaceCityKid
SpaceCityKid May. 12 at 5:46 PM
$COYA Beat on both earnings and revenue, not to mention FDA fast track. Big boys are taking notice. Looks like a probable "hammer" reversal.
0 · Reply
Jwa68
Jwa68 May. 12 at 5:29 PM
$COYA D.Boral, BTIG and Lakestreet all reiterated. $15 target,$16 target and $17 target respectively.
0 · Reply
zampy
zampy May. 12 at 5:18 PM
$COYA If we finish at the opening or above...We just announced that we essentially are going to the negotiating table in an enhanced position. Our financial position has become much stronger...ATM out of the way...is now set aside. Stroke if genius to get the ATM out there. Im not trading COYA this year with the massive potential upon us. Wirh Today's ANNOUNCEMENTS COYA IS HEATING UP RAPIDLY!!
0 · Reply
Jwa68
Jwa68 May. 12 at 5:14 PM
$COYA All the analysts are pounding the table. I will post some of them later. The FDA essentially just stated they will approve 302 with good phase 2 data. I think them doing this now is not random. ALS is a horrid disease with no standard of care. A highly unmet need that needs a drug yesterday. Clearly the FDA would appear to have reason to believe Coya may have one and they took a major surpise step to help possibly facilitate it. Speaks volumes...
1 · Reply
StreetwiseReports
StreetwiseReports May. 12 at 4:35 PM
FDA Fast Track Designation Boosts ALS Treatment Outlook; Analyst Sees More Than 250% Upside Potential https://ow.ly/WWPG50YYlC0 D. Boral Capital analyst Jason Kolbert reiterated his rating and price target on Coya Therapeutics Inc. ( $COYA ) following the company's receipt of FDA Fast Track Designation for COYA 302 in ALS.
0 · Reply
rubeytubes
rubeytubes May. 12 at 3:02 PM
$COYA good place to buy now ?
2 · Reply
irf944
irf944 May. 12 at 2:52 PM
$COYA Been adding today. Having that ATM is standard procedure for BioTech comapnies. They would have been negligent if they didn't have it in place. The story has not changed...it actually got better with today's news.
0 · Reply
zampy
zampy May. 12 at 2:51 PM
$COYA 30m Atm is smart...We have more chips at the table to negotiate with big pharma looming now with fast track. Saving on a 30m ATM are substantial...No warrants so no additional 6m to 30m...Clean Typical 7% on an offering...here approx 2%...an overnite would be 10% or 3m... This will be bought out wrll before we ever tap this 30m ATM...means iver the enduing months things are happening.. Very few expected this fast track..I got lucky with my call last week I believe the 3 names I mentioned will become reality in the next 4 months or so.
0 · Reply
zampy
zampy May. 12 at 2:38 PM
$COYA The 30m ATM will very very very likely never get used. It is a very smart negotiation tactic to sit at the table with the likes of Dr Reddy's...Sanofi...and Bristol Myers...BMY... Why did I mention these 3 names...Well BMY is abatacept CTLA4 50% of our therapy. Dr Arun Swaminathan worked there for 15 years and specifically on this drug. I am sure this is a possiblity now that the FDA fast tracked us...Sanofi well IL2 is manufactured by them our 2nd half of the therapy Dr Reddy's 700m milestone and now equity at $4.40 9.9%. Today will spark takeover talk with this significant advancement for fast track. And to me these are the obvious choices to look at our asset. Dr Reddy's has put in the leg work snd if they dont make a move soon they will be on outside looking in with the likes of BMY and Sanofi. This ATM was done for MORE LEVERAGE AT THE TABLE NEGOTIATING ...It is glaringly apparent to me. I believe this asset will go!
0 · Reply
EmotionlessRobot
EmotionlessRobot May. 12 at 2:11 PM
$COYA Never anything wrong with raising cash at the correct times imo. It may seem odd given the agreement we have with Reddys and the 50 mil in the bank but this ATM derisks us getting to full phase 2 results and potentially starting phase 3 (which I believe will still happen even with accelerated approval).
1 · Reply
Jwa68
Jwa68 May. 12 at 2:09 PM
$COYA Tremendous opportunity in my mind. Rarely seen or afforded.
1 · Reply
ForestFoxes
ForestFoxes May. 12 at 2:06 PM
$COYA Thanks @Cinderblocks Part of me has to wonder whether it would have been more advantageous for the company to have waited a couple of days or a week so that the news of the FDA Fast Track approval could stand on its own w/o being immediately paired with this 30M dilution. Let's hope COYA and their assigned sales agent, Leerink Partners LLC, does a good job and these shares are bought up quickly.
1 · Reply
ForestFoxes
ForestFoxes May. 12 at 1:48 PM
$COYA is trending downwards -5.5% to $3.95 which I find interesting particularly since I was buying pre-market just a little while ago at $4.25. I'm looking forward to where this goes in the coming weeks/months. Good luck everyone : )
0 · Reply
zampy
zampy May. 12 at 1:48 PM
$COYA 30m is good housekeeping..no biggie..Im buying...
0 · Reply